Richard Shames

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

Kim Papp, Diamant Thaçi, Kristian Reich et al. · British Journal of Dermatology · 2015 · 268 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma

Elliot Israel, Harold S. Nelson, James Baker et al. · American Journal of Respiratory and Critical Care Medicine · 2008 · 147 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Gert Van Assche, William J. Sandborn, Brian G. Feagan et al. · Gut · 2006 · 146 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Robert B. Nussenblatt, Darby J. S. Thompson, Zhuqing Li et al. · Journal of Autoimmunity · 2003 · 119 citations

Medicine, Immunology, Pharmacotherapy +15

Agreement Among Measures of Asthma Status: A Prospective Study of Low-Income Children With Moderate to Severe Asthma

Paul J. Sharek, Michelle L. Mayer, Lisa Loewy et al. · PEDIATRICS · 2002 · 86 citations

Health Professions, Child Health, Pediatrics +15